Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.38 |
| ▸ | CDK7 | P50613 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055625 | 0.96 | CHEK1 (0.39) | CHEK1CDK7MMP13KDM4C | |
| SCHEMBL5061555 | 0.84 | HPN (0.41) | CHEK1CDK7MMP13 | |
| SCHEMBL5051856 | 0.83 | CHEK1 (0.41) | CHEK1CDK7MMP13KDM4C | |
| SCHEMBL5054001 | 0.83 | KDM4C (0.36) | KDM4C | |
| SCHEMBL5051812 | 0.82 | PRMT5 (0.40) | CHEK1CDK7MMP13 | |
| SCHEMBL5058943 | 0.81 | CHEK1 (0.38) | CHEK1CDK7MMP13KDM4C | |
| SCHEMBL5054018 | 0.79 | KDM4C (0.37) | CHEK1KDM4C | |
| SCHEMBL5051829 | 0.77 | CHEK1 (0.50) | CHEK1CDK7 | |
| SCHEMBL5055582 | 0.75 | CHEK1 (0.62) | CHEK1CDK7 | |
| SCHEMBL27708461 | 0.73 | CHEK1 (0.45) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CHEK1 1/4885CDK7 43/4885MMP13 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.